证券代码：688575 证券简称：亚辉龙 公告编号：2025-064 深圳市亚辉龙生物科技股份有限公司 重要内容提示： 会议召开时间：2025 年 12 月 3 日（星期三）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 为提高交流效率，深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）现 提前向投资者征集相关问题，欢迎广大投资者于 2025 年 11 月 26 日（星期三） 至 12 月 2 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集" 栏目或通过公司投资者关系邮箱 ir@szyhlo.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 3 日（星期三）15:00-16:00 举行 2025 年第三季度业绩说明会，就 投资者关心的问题进行交流。 一、说明 ...

机构持仓方面，截止2025年9月30日，亚辉龙十大流通股东中，华宝中证医疗ETF（512170）位居第七 大流通股东，持股965.16万股，相比上期减少176.69万股。 责任编辑：小浪快报 截至9月30日，亚辉龙股东户数1.28万，较上期增加7.40%；人均流通股44595股，较上期减少6.89%。 2025年1月-9月，亚辉龙实现营业收入12.87亿元，同比减少7.69%；归母净利润6042.09万元，同比减少 72.36%。 分红方面，亚辉龙A股上市后累计派现6.93亿元。近三年，累计派现5.31亿元。 11月21日，亚辉龙跌3.68%，成交额9994.92万元。两融数据显示，当日亚辉龙获融资买入额1253.69万 元，融资偿还1579.12万元，融资净买入-325.43万元。截至11月21日，亚辉龙融资融券余额合计4.45亿 元。 融资方面，亚辉龙当日融资买入1253.69万元。当前融资余额4.43亿元，占流通市值的5.21%，融资余额 超过近一年70%分位水平，处于较高位。 融券方面，亚辉龙11月21日融券偿还0.00股，融券卖出400.00股，按当日收盘价计算，卖出金额5964.00 元；融券余量 ...

Core Insights - The article presents the results of quality management system inspections for medical device registrations in October 2025, highlighting the compliance status of various companies and their products [2][3] Group 1: Company Compliance Results - Shenzhen Huian Biological Technology Co., Ltd. successfully passed the inspection for the Influenza Virus Antigen Detection Kit after rectification on October 8, 2025 [2] - Shenzhen Yihuilong Biotechnology Co., Ltd. passed the inspection for the EB Virus Antigen IgG Antibody Detection Kit on October 8, 2025 [2] - Shenzhen Gamma Knife Technology Co., Ltd. passed the inspection for the Head Gamma Ray Stereotactic Radiotherapy System after rectification on October 10, 2025 [2] - Shenzhen Jingfeng Medical Technology Co., Ltd. passed the inspection for the Single-Port Laparoscopic Surgery System after rectification on October 15, 2025 [2] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. passed multiple inspections for various medical testing kits and products between October 17 and October 22, 2025 [2][3] Group 2: Product Categories - The inspected products include diagnostic kits for various viruses, surgical systems, and medical imaging devices, indicating a diverse range of medical technologies being evaluated [2][3] - The successful inspections reflect the companies' adherence to quality management standards set by the Guangdong Provincial Drug Administration [3] Group 3: Regulatory Context - The inspections are part of a regulatory framework established by the Guangdong Provincial Drug Administration, which began notifying applicants of inspection results via SMS or web queries since May 2022 [3]

Core Points - Shenzhen Yahui Long Biotechnology Co., Ltd. has received a medical device registration certificate from the Guangdong Provincial Drug Administration, marking a significant milestone for the company [1][2]. Group 1: Medical Device Registration - The registered product is an automatic fluorescence immunoassay analyzer, capable of quantitative or qualitative detection of analytes in human serum and plasma samples [1]. - The analyzer has a maximum processing capacity of 72 samples per hour and can simultaneously test multiple different biomolecules, allowing for multiplex testing [1]. Group 2: Market Impact - The acquisition of the registration certificate represents a breakthrough for the company in the field of multiplex detection, enhancing its core competitiveness and market expansion capabilities [2]. - The liquid phase multiplex detection platform, which is being applied in the field of autoantibody detection, reflects the company's innovative spirit and commitment to advancing autoantibody testing in China [2].

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-062 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）于近日收 到了由广东省药品监督管理局签发的医疗器械注册证，具体信息如下： | 序 | 产品名称 | 注册编号 | 注册证有效期 | 注册 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 分类 | | | 1 | 全自动荧光免疫分析仪 | 粤械注准 | 至 2030/11/17 | 二类 | 采用基于藻红蛋白的磁条码免疫荧光发光 法，与亚辉龙生产的检测试剂共同使用，在 | | | | 20252221513 | | | 临床上用于对来源于人体的血清、血浆样本 | | | | | | | 中的被分物进行定性或定量检测。 | 一、医疗器械注册证的基本情况 二、对公司的影响 亚辉龙全自动荧光免疫分析仪是一款全自动 ...

Core Viewpoint - The company has received a medical device registration certificate for its fully automated fluorescent immunoassay analyzer, which is expected to enhance its competitiveness and market expansion capabilities, although the impact on performance remains uncertain due to various influencing factors [1] Group 1: Product Registration - The company received the medical device registration certificate from the Guangdong Provincial Drug Administration [1] - The registration number is 粤械注准20252221513, and it is valid until November 17, 2030 [1] - The analyzer is classified as a Class II medical device [1] Group 2: Product Capabilities - The analyzer can test human serum and plasma samples [1] - It has a maximum processing capacity of 72 samples per hour [1] Group 3: Market Implications - The certification represents a breakthrough for the company in the field of multi-detection [1] - The sales performance of the product will be influenced by various factors, making the impact on financial performance unpredictable [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-060 深圳市亚辉龙生物科技股份有限公司 关于控股股东、实际控制人兼董事长及其一致行动人 权益变动触及 1%整数倍的提示性公告 控股股东、实际控制人兼董事长及其一致行动人保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 47.06% | | | | 权益变动后合计比例 | 46.96% | | | | 本次变动是否违反已作出的承 | 是□ | 否√ | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2025-061 深圳市亚辉龙生物科技股份有限公司 关于向银行申请抵押贷款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司向银行申请抵押贷款基本情况 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）于 2021 年 8 月 26 日召 开第二届董事会第十九次会议，审议通过了《关于向银行申请抵押贷款的议案》。为满 足公司宝龙二期产业园项目（现名：启德大厦项目）建设需要，改善公司现金流状况、 降低经营风险、促进公司经营发展，公司拟以部分自有资产作为抵押，向商业银行申请 不超过人民币 6 亿元贷款，最终贷款金额、贷款期限、贷款利率等以银行审批为准，并 授权公司董事长及/或其授权代表在上述贷款金额及贷款期限内与相关银行签署贷款协 议、担保协议及其他相关文件（包括该等文件的修正及补充）并办理相关手续，授权期 限至前述事项办理完毕为止。 根据上述授权，公司向招商银行股份有限公司深圳分行（以下简称"招商银行深圳 分行"）申请不超过人民币 59,200 万元的固定 ...

Core Viewpoint - The company, Aihuilong (688575.SH), announced that its controlling shareholder and chairman, Hu Kunhui, reduced his shareholding through a block trade, impacting the overall ownership structure of the company [1] Group 1 - Hu Kunhui reduced his shareholding by selling a total of 600,000 shares on November 17-18, 2025 [1] - After the reduction, Hu Kunhui and his concerted parties hold a total of 267,851,515 shares, decreasing their combined ownership percentage from 47.06% to 46.96% [1] - The change in equity ownership triggered a 1% integer change in the shareholding structure [1]